A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi. ##STR00001##

A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi. ##STR00001##

The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charged under physiological conditions, and their use for serum resistant transfection of cells.

The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charged under physiological conditions, and their use for serum resistant transfection of cells.

Provided are compounds of Formula (I):

##STR00001##

and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

Provided are compounds of Formula (I):

##STR00001##

and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).

Aspects of the present application relate to process for the preparation of Omecamtiv mecarbil and salts thereof. Specific aspects relate to novel urea intermediate, preparative process thereof and its use in the preparation of Omecamtiv mecarbil and salts thereof. The improved process for the preparation of Omecamtiv mecarbil are industrially viable.

Aspects of the present application relate to process for the preparation of Omecamtiv mecarbil and salts thereof. Specific aspects relate to novel urea intermediate, preparative process thereof and its use in the preparation of Omecamtiv mecarbil and salts thereof. The improved process for the preparation of Omecamtiv mecarbil are industrially viable.

Aspects of the present application relate to solid forms of Omecamtiv mecarbil dihydrochloride. Specific aspects relate to crystalline forms and amorphous solid dispersions of Omecamtiv mecarbil dihydrochloride. Further specific aspects related to crystalline forms DP1, DP2, DP3, DP4, OMT-D, OMT-L, OMT-O, OMT-F, OMT-FS and amorphous solid dispersions of Omecamtiv mecarbil dihydrochloride and pharmaceutical compositions thereof.

Aspects of the present application relate to solid forms of Omecamtiv mecarbil dihydrochloride. Specific aspects relate to crystalline forms and amorphous solid dispersions of Omecamtiv mecarbil dihydrochloride. Further specific aspects related to crystalline forms DP1, DP2, DP3, DP4, OMT-D, OMT-L, OMT-O, OMT-F, OMT-FS and amorphous solid dispersions of Omecamtiv mecarbil dihydrochloride and pharmaceutical compositions thereof.